Pfizer Inc.
Tofacitinib oral sustained release dosage forms
Last updated:
Abstract:
The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
Status:
Grant
Type:
Utility
Filling date:
13 Mar 2020
Issue date:
22 Feb 2022